Radiopharm Theranostics (ASX:RAD) Total Stockholders Equity: A$44.79 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Radiopharm Theranostics Total Stockholders Equity?

Radiopharm Theranostics ASX:RAD Total Stockholders Equity is A$44.79 Mil as of Jun. 2025. The stock has 5 warning signs investors should review.

Radiopharm Theranostics's Total Stockholders Equity for the quarter that ended in Jun. 2025 was A$44.79 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Radiopharm Theranostics's Book Value per Share for the quarter that ended in Jun. 2025 was A$0.02. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Radiopharm Theranostics's Debt-to-Equity for the quarter that ended in Jun. 2025 was 0.00.

Radiopharm Theranostics  (ASX:RAD) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Radiopharm Theranostics's Book Value per Share for the quarter that ended in Jun. 2025 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(44.792-0)/2364.950
=0.02

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Radiopharm Theranostics's Debt-to-Equity for the quarter that ended in Jun. 2025 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 44.792
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radiopharm Theranostics Total Stockholders Equity Related Terms

Radiopharm Theranostics Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Radiopharm Theranostics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radiopharm Theranostics Total Stockholders Equity Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Total Stockholders Equity
62.96 44.38 28.12 44.79

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Total Stockholders Equity Get a 7-Day Free Trial 44.38 24.23 28.12 53.20 44.79
What does a Total Stockholders Equity of A$44.79 Mil mean?
Radiopharm Theranostics (ASX:RAD) has a Total Stockholders Equity of A$44.79 Mil as of Jun. 2025. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Radiopharm Theranostics and its competitors.
Is Radiopharm Theranostics' Total Stockholders Equity too high?
Radiopharm Theranostics' current Total Stockholders Equity is A$44.79 Mil.
How does Radiopharm Theranostics' Total Stockholders Equity compare to VRTX and REGN?
Radiopharm Theranostics' Total Stockholders Equity of A$44.79 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Radiopharm Theranostics and its competitors. Radiopharm Theranostics's current Total Stockholders Equity is A$44.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Radiopharm Theranostics (ASX:RAD) has a current Total Stockholders Equity of A$44.79 Mil. The current Total Stockholders Equity is A$44.79 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Radiopharm Theranostics (ASX:RAD), the current Total Stockholders Equity is A$44.79 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Radiopharm Theranostics Business Description

Other Exchanges RADX:USA
Address 62 Lygon Street, Suite 1, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.